Subtype
Ovarian Neoplasm
CI-CAN-00001335Explore in graph →
Non-malignant746 active trials5 approved drugs94 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001335Explore in graph →
Clinical trials
3,430 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02429687 | TC or BEP in Treating Patients With Malignant Ovarian Germ Cell Tumors(MOGCT-01) | recruiting | Phase 3 | 129 | Beihua KongOTHER | 1 | Apr 25, 2023 | clinicaltrials |
| NCT02429700 | TC or BEP in Treating Patients With Ovarian Malignant Sex Cord-Stromal Tumors(SCST-01) | recruiting | Phase 3 | 132 | Beihua KongOTHER | 1 | Apr 25, 2023 | clinicaltrials |
| NCT03458221 | Signal TrAnsduction Pathway Activity Analysis in OVarian cancER(STAPOVER) | recruiting | Phase 2 / Phase 3 | 148 | Gynaecologisch Oncologisch Centrum ZuidOTHER | 1 | Apr 18, 2023 | clinicaltrials |
| NCT05810701 | FRAGINOC Study: Screening and Geriatric Assessment and Intervention in Older Patients With Epithelial Ovarian Cancer(FRAGINOC) | recruiting | N/A | 300 | Odense University HospitalOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT05255471 | MITO 35B: Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer Patients.(MITO 35B) | recruiting | Phase 3 | 200 | National Cancer Institute, NaplesOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT01763125 | Establishment of a Tumor Bank for Blood Samples | recruiting | — | 10,000 | Medical University of ViennaOTHER | 4 | Mar 23, 2023 | clinicaltrials |
| NCT01789229 | Establishment of a Tumor Bank for Tissue Samples | recruiting | — | 10,000 | Medical University of ViennaOTHER | 3 | Mar 23, 2023 | clinicaltrials |
| NCT05733000 | CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors | recruiting | Phase 2 | 94 | Northwestern UniversityOTHER | 1 | Mar 10, 2023 | clinicaltrials |
| NCT05607329 | Secondary Cytoreduction Followed by Chemotherapy Versus Chemotherapy Alone in Relapsed Ovarian Cancer After PARPi Maintenance Treatment: a Multicentre, Open-label, Randomised, Phase 3 Trial | recruiting | N/A | 400 | Women's Hospital School Of Medicine Zhejiang UniversityOTHER | 1 | Nov 7, 2022 | clinicaltrials |
| NCT05551208 | Fluzoparib Combined With Bevacizumab in PSROC Previously Treated With PARPi | recruiting | Phase 2 | 42 | Chongqing University Cancer HospitalOTHER | 1 | Sep 22, 2022 | clinicaltrials |
| NCT05030805 | Transcriptional Map of Ovarian Cancer at the Single Cell Level(Ova-seq) | recruiting | — | 50 | University Hospital, Strasbourg, FranceOTHER | 1 | Aug 22, 2022 | clinicaltrials |
| NCT04520074 | Adjuvant Chemotherapy of Three-step Regimen in BRCA1/2 Wide Type Ovarian Cancer (ACTS-2) | recruiting | Phase 3 | 590 | Fudan UniversityOTHER | 1 | Jul 27, 2022 | clinicaltrials |
| NCT05450055 | Intraperitoneal Lidocaine in Ovarian Cancer Surgery | not yet recruiting | N/A | 60 | Peking University Third HospitalOTHER | 1 | Jul 13, 2022 | clinicaltrials |
| NCT03836352 | Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors | active not recruiting | Phase 2 | 184 | ImmunoVaccine Technologies, Inc. (IMV Inc.)INDUSTRY | 2 | Mar 31, 2022 | clinicaltrials |
| NCT05242861 | Retrospective Study of Brachytherapy(RetroBT) | recruiting | — | 300 | Zhejiang Cancer HospitalOTHER | 1 | Feb 16, 2022 | clinicaltrials |
| NCT05206890 | A Non-interventional Registry Study of Fluzoparib in the Treatment of Ovarian Cancer | recruiting | — | 490 | Tongji HospitalOTHER | 1 | Jan 26, 2022 | clinicaltrials |
| NCT05172310 | PET Imaging of Solid Tumors by a Novel Tracer, 68Ga-FAPI | recruiting | Phase 1 | 410 | Karolinska University HospitalOTHER | 1 | Dec 29, 2021 | clinicaltrials |
| NCT02073500 | Peritoneal Surface Malignancies - Characterization, Models and Treatment Strategies(PSM) | recruiting | — | 300 | Oslo University HospitalOTHER | 1 | Jul 28, 2021 | clinicaltrials |
| NCT03787056 | Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer Patients(ONCOPRO) | recruiting | N/A | 410 | Hospices Civils de LyonOTHER | 1 | Jul 16, 2021 | clinicaltrials |
| NCT03025477 | Two Therapeutic Strategies in First-line in Patients With Epithelial Advanced Ovarian Cancer(CHIMOVIP) | recruiting | Phase 2 | 84 | Groupe Hospitalier Diaconesses Croix Saint-SimonOTHER | 1 | Feb 11, 2021 | clinicaltrials |
| NCT04451369 | Connected Prehabilitation Program During Neo Adjuvant Chemotherapy(TRAINING) | not yet recruiting | N/A | 136 | Institut Paoli-CalmettesOTHER | 0 | Feb 10, 2021 | clinicaltrials |
| NCT04714957 | PITCHER (Peritoneal Carcinomatosis Heterogeneity) | recruiting | — | 20 | Hospices Civils de LyonOTHER | 1 | Jan 20, 2021 | clinicaltrials |
| NCT04710797 | Lymphadenectomy in Early Ovarian Cancer(LOVE) | recruiting | N/A | 656 | Sun Yat-sen UniversityOTHER | 1 | Jan 15, 2021 | clinicaltrials |
| NCT04515602 | Stratified Evaluation of PDS and NACT-IDS in Ovarian Cancer (FOCUS) | not yet recruiting | Phase 3 | 410 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 1 | Aug 27, 2020 | clinicaltrials |
| NCT03667417 | Genetic Predisposition to Breast and Ovarian Cancer: Prospective Study of BRCAx Gene Mutation(GENEPSO) | recruiting | — | 5,000 | Institut Paoli-CalmettesOTHER | 1 | Jul 1, 2020 | clinicaltrials |
| NCT04063527 | Phase III Trial of Stage I Ovarian Cancer After Surgery | recruiting | Phase 3 | 360 | Japanese Gynecologic Oncology GroupOTHER | 2 | Aug 30, 2019 | clinicaltrials |
| NCT02803970 | KOrean Borderline Ovarian Tumor (KOBOT) Registry(KOBOT) | recruiting | — | 3,000 | Kangbuk Samsung HospitalOTHER | 1 | Apr 3, 2019 | clinicaltrials |
| NCT01000259 | Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer | recruiting | — | 174 | Gynecologic Oncology GroupNETWORK | 1 | May 5, 2017 | clinicaltrials |
| NCT02869568 | Institut Paoli Calmettes Ovarian Cancer Database | recruiting | — | 6,000 | Institut Paoli-CalmettesOTHER | 1 | Aug 17, 2016 | clinicaltrials |
| NCT02487693 | Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Ovarian Carcinoma | active not recruiting | Phase 2 | 50 | The First People's Hospital of ChangzhouOTHER | 0 | Feb 23, 2016 | clinicaltrials |
Data updated 22 days agoSource updated Apr 25, 2023source: clinicaltrials